State-of-the-art therapies for fragile X syndrome.
Dragana Protic, Randi Hagerman
PMID 38385885WHAT IT FOUND
Current therapies for fragile X syndrome manage symptoms but do not cure the underlying genetic cause.
Pharmacological options like stimulants and SSRIs target specific behaviors, while gene therapies remain in preclinical stages.
Key findings
01There is currently no cure for fragile X syndrome, and pharmacotherapy aims to treat symptoms such as ADHD, anxiety, aggression, and sleep problems.
02Stimulants are effective in approximately 70% of individuals with ADHD symptoms, but high doses can suppress language abilities.
03Gene therapy strategies, including ASO and AAV vector therapy, have not yet advanced to human trials for fragile X syndrome.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a narrative review, not a systematic review, so the selection of studies may reflect author bias. Many of the 'targeted treatments' discussed (metformin, CBD, BPN14770) are based on small sample sizes, open-label studies, or preclinical animal models. Gene therapy findings are almost exclusively from animal or cell studies, with no human trial data yet.
Declared interests
The provided text does not contain a conflict of interest or funding declaration section.
The easy way to misread this
Do not interpret the promising results for targeted treatments like metformin or CBD as established standard of care. Most evidence for these agents comes from small, open-label studies or animal models, and large controlled trials are still pending or recent.